Kornimate/medical-research-clean huggingface dataset:
improving engagement in hiv and cancer care in zimbabwe

Conditions: Cancer; HIV

Summary: in zimbabwe, people who have cancer and hiv may have a difficult time staying engaged in their hiv care while they are being treated for cancer. this is because hiv and cancer care are usually provided at different health facilities, which can result in barriers to accessing clinical care for both hiv and cancer at the same time. it is important to remain engaged in hiv care, and continue taking medication to treat hiv throughout cancer treatment. the goal of this project is to identify barriers that make it difficult to stay engaged in hiv care and continue hiv treatment during cancer treatment and develop strategies to address them. we will accomplish this by first observing a group of 150 people with cancer and hiv who are receiving cancer treatment at parirenyatwa hospital, in harare, zimbabwe. we will measure barriers to accessing hiv care, and disruptions to hiv care engagement during cancer treatment. next, we will work with experts and key stakeholders to develop strategies that can be put in place at parirenyatwa hospital to better support engagement in hiv care during cancer treatment. we will work with the cancer ward at the hospital to implement these strategies. finally, we will observe a second group of 150 people with cancer and hiv, who begin their cancer treatment at parirenyatwa hospital after the strategies have been put in place. we will measure acceptability of these strategies to both patients and hospital staff. we will also measure barriers to accessing hiv care and disruptions to hiv care engagement in the second group. we will compare barriers to hiv care and hiv care engagement in the second group to the first group, to determine whether the strategies make it easier for people with cancer and hiv to remain engaged in hiv care during cancer treatment.


Eligibility criteria:
inclusion criteria: * age 18 or older * registered patient at parirenyatwa hospital radiotherapy centre, receiving cancer treatment for a new diagnosis * hiv-positive exclusion criteria: * benign diagnosis or cancer recurrence
capture - complete automatic pacing threshold utilization recorded by enpulse

Conditions: Arrhythmia; Bradycardia

Summary: this study compares the pacemaker's automatic pacing threshold measurements to the manual measurements conducted by a health care provider.

the purpose(s) of the study is (are) to evaluate several features available in enpulse series pacemaker and report the long term benefit of atrial capture management (acm) and ventricular capture management (vcm) as demonstrated by accuracy in comparison with manual measurements and variability of acm and vcm thresholds. in addition, an evaluation of the timesaving and qualitative benefits of the device feature known as quick look ii (the computer interface screen of the device programmer) will be measured through the use of a questionnaire completed by the health care professionals involved in patient follow-up care. this is a one-to-one randomized, multicenter, prospective study in which patients receiving new enpulse pacemaker implants will be randomized to each of three study arms, 1) routine manual follow-up and follow-up using the automatic features; 2) acm diagnostics detail on or vcm diagnostics detail on; 3) pmop on / off or pmop off / on (6 month cycle).

Eligibility criteria:
inclusion criteria: • patients that meet acc/aha/naspe 2002 class i or ii dual chamber pacing indications (intended for a pacing mode programmed to ddd or dddr) exclusion criteria: * patient with mechanical tricuspid heart valves * patients with medical conditions that preclude the testing required by the protocol or limit study participation

Keywords: arrhythmia bradycardia cardiac pacemaker artificial
mobile application for educating diabetics about foot care

Conditions: Diabetic Foot, Mobile Application, Patient Education

Summary: purpose: our aim was to develop a training program on the mobile application and to assess the effect of this training on the participants' knowledge about foot care, their self-efficacy and their behavior levels.

the universe of this randomized controlled study consisted of 130 patients who had presented to a training and research hospital in istanbul. the data were collected during the period march-september 2017 with an information form, the diabetic foot knowledge scale, diabetic foot care self-efficacy scale, foot self-care behavior scale and a feedback form on the mobile application training.

Eligibility criteria:
inclusion criteria: * diagnosed as a type 2 diabetic according to ada criteria at least six months prior to the study, * being 18 years of age and over, * being literate and fluent in turkish, * not having an active foot ulcer, * owning and being able to operate a smart phone, * not having any communication or mental problems, * consenting to participating in the research. exclusion criteria: * patients with advanced retinopathy and those wishing to withdraw from the research were excluded from the study.

Keywords: diabetic foot, mobile application, patient education
role of alprazolam in the management of acute coronary syndrome

Conditions: Acute Coronary Syndrome; Myocardial Infarction; ST Elevation Myocardial Infarction; Heart Diseases; Anxiety

Summary: cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. on one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. hence leading to up slopping trend in cardiovascular prevalence. acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. one of the fundamental goals in the treatment of acs is to lower the heart rate so that load on myocardial tissue can be reduced. in order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

world has studied the increased prevalence of anxiety as a concomitant factor in acs patients causing detrimental effects on cardiovascular outcomes being anxiety as one of the first responses to chest pain and hospital admission causing tachycardia. this study is designed to achieve the goals of lowering the heart using the anxiolytic property of alprazolam. this randomized, parallel group, close label, placebo-controlled, event driven, interventional clinical superiority study will be conducted in cardiology department of shaikh zayed hospital with a sample size of 48 allocating using lottery method in both experimental and control group. heart rate at baseline and after 6 hours will be monitored in both groups to establish the fall of heart rate in both patients. data will be collected by using pre-designed performa and will be entered and analyzed via sas 9.4. statistical analysis will be done using t-test and p value \<0.05 will be considered significant. significance of the study is to lower the required dosage of beta-blockers in order to achieve optimum beta-blockade using an anxiolytic while not affecting the blood pressure.

Eligibility criteria:
inclusion criteria: systolic bp\>100mm hg age between 18-80 years sinus rhythm exclusion criteria: * cardiogenic shock / hypotension * known asthma/copd * bradycardia (hr \< 60) * already on beta blockers/ anxiolytics * sick sinus syndrome * second or third-degree heart block (in the absence of pacemaker) * decompensated heart failure * with documented hypersensitivity to the drug or components * valvular heart diseases * congenital heart diseases * status post cabg * any co-morbidities except diabetes mellitus and hypertension

Keywords: cardiology acute coronary syndrome heart rate alprazolam anxiolytic
the effects of an exercise programme for older patients with heart failure

Conditions: Heart Failure; Old Age; Debility

Summary: patients with heart failure have decreased exercise tolerance, balance problems, and fall risks. the purpose of this research was to investigate the effect of an exercise program based on the empowerment model for participants with heart failure. this randomized, controlled study including pre-test/post-test and the measurements were performed between january-november 2014 at a university hospital in izmir, turkey. intervention group (n = 11) and control group (n = 10) participated in the research. the intervention group received 45-60 minute individual training and 12 weeks of individual follow-up. the weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. patients in the control group did not receive any intervention except for their routine treatment. data were collected before the education of exercise and after 12 weeks; sociodemographic data questionnaire, pedometer, accelerometer, berg balance scale, hf empowerment scale, estimated weekly exercise monitoring form and exercise booklet had been utilised. the spss statistical package program was used to analyze the data.

patients with heart failure have decreased exercise tolerance, balance problems, and fall risks. the purpose of this research was to investigate the effect of an exercise program based on the empowerment model for participants with heart failure. this randomized, controlled study including pre-test/post-test and the measurements were performed between january-november 2014 at a university hospital in izmir, turkey. intervention group (n = 11) and control group (n = 10) participated in the research. the intervention group received 45-60 minute individual training and 12 weeks of individual follow-up. the weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. patients in the control group did not receive any intervention except for their routine treatment. data were collected before the education of exercise and after 12 weeks; sociodemographic data questionnaire, pedometer, accelerometer, berg balance scale, hf empowerment scale, estimated weekly exercise monitoring form and exercise booklet had been utilised. the spss statistical package program was used to analyze the data.

Eligibility criteria:
inclusion criteria: * were aged 60 years or older * independent * literate * able to communicate verbally * participating voluntarly in the study exclusion criteria: * were having a diagnosis of psychiatric illness * a visual or auditory impairment * previously participated in another exercise program * any contraindication to exercise (uncontrolled arrhythmia, hypertension and metabolic illness, ejection fraction)

Keywords: aging randomized controlled trials (rct) nursing physical activity
a dose-finding study of opc-6535 in patients with active crohn's disease

Conditions: Crohn Disease

Summary: the purpose of this study to examine the safety and efficacy of opc-6535 and determine its optimal dose by once-daily oral administration at 0, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic acid (5-asa) or in combination with a fixed oral dose of 5-asa and enteral nutrition in patients with active crohn's disease.


Eligibility criteria:
inclusion criteria: * patients with active crohn's disease * patients who have a primary lesion in either the small intestine or the large intestine * patients who have been receiving an oral 5-asa formulation at a fixed regimen and at a fixed dose * patients who have either never received enteral nutrition or have been receiving enteral nutrition at a fixed intake of 1200 kcal/day or less * either inpatient or outpatient exclusion criteria: * patients who have an external fistula (including anal fistula) in which persistent drainage is observed (and who require treatment with antibiotics or synthetic antibacterial agents) * patients with short bowel syndrome (and who require intravenous nutritional support due to insufficient intestinal nutrient uptake) * patients with an artificial anus * patients who have a complication of serious infectious disease (intra-abdominal abscess, etc.) * patients who have a complication of malignant tumor * female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the study period

Keywords: opc-6535 crohn's disease
brivaracetam as add-on treatment of unverricht-lundborg disease in adolescents and adults

Conditions: Unverricht-Lundborg Disease

Summary: the study will compare the efficacy and safety of brivaracetam with placebo in patients with unverricht-lundborg disease.


Eligibility criteria:
inclusion criteria: * subjects with diagnosed unverricht-lundborg disease (uld) ascertained by appropriate genetic testing for a homozygous or compound heterozygous mutation in the cystatin b (cstb) gene * subjects with moderate to severe myoclonus documented by an action myoclonus sum score of ≥ 30 (evaluation by investigator) * subjects currently being or having been treated with clonazepam up to the maximum recommended daily dose of 20 mg or up to their individual optimal dose as assessed by the investigator * subjects currently being or having been treated with valproate up to the maximum recommended daily dose 60 mg/kg or serum levels of 100 mcg/ml or up to their individual optimal dose as specified by the investigator exclusion criteria: * subjects currently on felbamate or having been on felbamate within less than 18 months prior to visit 1 * subjects currently treated with phenytoin or having been on phenytoin in the last month prior to visit 1 * subjects currently on vigabatrine. subjects having been on vigabatrine if no visual fields examination report available including standard static (humphrey or octopus) or cinetic perimetry (goldman) * subject taking any drug with possible central nervous system (cns) effects * subjects taking any drug that may significantly influence the metabolism of brv (cyp2c or cyp3a potent inducers/inhibitors) * known clinically significant acute or chronic illness or illness which may impair reliable participation in the trial, necessitate the use of medication not allowed by protocol or represent a safety risk in the investigator's opinion * subjects with history of severe adverse hematological reaction to any drug * impaired hepatic function: alat/sgpt, asat/sgot, alkaline phosphatase, ggt value of more than three times the upper limit of the reference range * history of suicide attempt during the last 5 years * subject with suicidal ideations within the last year or at risk of suicide attempt unless cleared by written confirmation from a psychiatrist and approved by the ucb physician * ongoing psychiatric disorder other than mild controlled disorder

Keywords: unverricht-lundborg disease baltic myoclonus progressive myoclonic epilepsies myoclonus brivaracetam
clinical tolerance and equivalence of hcg-ibsa vs recombinant human chorionic gonadotrophin in women undergoing in vitro fertilisation

Conditions: Infertility

Summary: the purpose of the study is to evaluate the clinical equivalence and the general tolerability of two different subcutaneous hcg preparations (hcg-ibsa, ibsa vs ovitrelle, serono) when administered to patients undergoing ivf.

this is a prospective, multicenter, randomized, investigator blind, parallel group, active control, phase iii clinical trial. patients meeting the eligibility requirements of the study will be randomly assigned to receive either the test drug (hcg-ibsa, ibsa) or the reference drug (ovitrelle, serono). investigators will be blinded by not allowing them to have any contact with the study medications (supplied in boxes labeled in a manner that does not reveal the content of the boxes), and requesting that patients do not make any statements to the investigator that might indicate the treatment to which they were assigned. equivalence testing with regard to the primary outcome variable will establish whether the two treatments are indeed similarly effective.

Eligibility criteria:
inclusion criteria: * \>/=18 and \< 40 years old; * bmi between 18 and 30 kg/m2; * less than 3 previous completed cycles; * both ovaries present; * regular menstrual cycle of 25-35 days; * infertility attributable to a tubal factor, american fertility society grade i or ii endometriosis, male factor or unexplained factor. * within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through hysterosalpingogram, sonohystrogram or hysteroscopic examination; * basal fsh level less than 10 iu/l; * criteria for hcg administration fulfilled (at least 2 follicles with a diameter of 16 mm or more, with acceptable serum e2 concentration). * a male partner with semen analysis within the past 6 months showing acceptable values of seminal parameters, defined as \> 3x10 exp 6 spermatozoa/ml; * qualified to receive 150 - 300 iu fsh as starting dose. exclusion criteria: * age \ o = 40 years; * primary ovarian failure or women known as poor responders (i.e. requiring more than 300 iu of fsh as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with an e2 serum concentration \< 3'000 pmol/l); * ovarian cysts \> 20 mm, or enlargement not due to polycystic ovarian syndrome; * patients affected by pathologies associated with any contraindication of being pregnant; * hypersensitivity to the study medication; * any bleeding since stimulation; * uncontrolled thyroid or adrenal dysfunction; * neoplasias; * severe impairment of the renal and/or hepatic functions; * use of concomitant medication that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents); * more than 18 days of fsh stimulation.

Keywords: infertility, sterility, hcg, ivf
a study to describe the efficacy of diphereline following conservative surgery in deep infiltrating endometriosis (die) patients over a period of 24 months

Conditions: Deep Infiltrating Endometriosis (DIE)

Summary: the purpose of this study is to describe changes in the intensity of specific endometriosis symptoms from baseline pre-surgery to after surgery and subsequent continuous diphereline (triptorelin acetate) treatment for up to 24 weeks.


Eligibility criteria:
inclusion criteria: * patients diagnosed with die and having received surgery treatment within one month before inclusion * premenopausal women aged \>=18 years old. * written icf has been obtained prior to any study-related procedures * patient for whom the treating physician already made the decision to treat by diphereline. * patient should be mentally and physically able to express her symptom complaints and answer questions. exclusion criteria: * pregnancy or lactation. * patients currently on treatment or who have been on therapy with a gnrha in the last 6 months. * premenopausal women who may reach menopause within the 3 years post randomisation. * hypersensitivity to triptorelin or one of the excipients of triptorelin 3.75mg * treatment with another research drug over the last 3 months before the study * potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.

Keywords: endometriosis
head and neck cancer patient symptom and oncologic outcomes

Conditions: Lymphedema of the Head and Neck

Summary: this trial investigates a new approach using a mobile three-dimensional (3d) scanning application for volumetric measurement of the head and neck region in patients with head and neck lymphedema. lymphedema is the buildup of extra lymph fluid in tissues that causes swelling. accurate volumetric measurements of swelling are crucial to the diagnosis of lymphedema and to monitoring response to therapy and disease progression over time. a mobile 3d surface scanning application may help doctors measure and analyze swelling in patients with head and neck lymphedema.

primary objectives: i. to develop a specialized and mobile 3d surface scanning application to assess and monitor head and neck lymphedema. ii. to confirm optimal positioning when volumetrically assessing head and neck lymphedema using 3d technologies as consistent with standard plastic surgery departmental protocol. iii. to quantify and serially track changes in head and neck lymphedema in patients with pathologies and correlate these changes with overall patient well-being and disease progression. outline: patients undergo 3d scanning of lower head and neck region over 90-120 seconds before surgery and then every 3 months for up to 1 year after surgery.

Eligibility criteria:
inclusion criteria: * patients with pathologies leading to head and neck lymphedema * individuals with minimal or no facial hair * patients of sound mentation, who are able to execute informed decision-making exclusion criteria: * any health conditions or history of non-compliance that affect the study will preclude study participation
electronic defaults to reduce opioid prescribing in dentistry practices

Conditions: Acute Pain

Summary: the goal of this research is to investigate the impact of changing opioid analgesic prescribing defaults on the quantity of opioids prescribed for acute non-cancer pain in adult dentistry settings. we will change prescribing defaults for select short-acting opioid analgesics including immediate release oxycodone and hydrocodone as well as codeine and tramadol, including their co-formulations with acetaminophen. in a cluster-randomized trial of three montefiore medical center dentistry sites, we will evaluate the impact of this intervention on patient-level outcomes using 18 months of data (6 months pre-intervention and 12 months post-intervention).


Eligibility criteria:
clinical site inclusion criteria: * dentistry clinic within montefiore medical center patient inclusion criteria: * received a new opioid analgesic prescription, defined as no opioid analgesic prescription in the preceding 6 months exclusion criteria: * none
comparison of nose and conventional methods in laparoscopic total colon surgery

Conditions: Surgical Incision

Summary: laparoscopic total colectomy (ltc) is an accepted surgical procedure for several colonic pathologies. additionally, specimen extraction through the natural orifices is an emerging method when combined with the totally laparoscopic procedures. our observations on natural orifice surgery was promising . in our daily surgical practice, investigators prefer the intracorporeal anastomosis and this study was conducted to compare the specimen extraction sites after ltc. here investigators aimed to compare the results of conventional and natural orifice specimen extractions (nose) after totally ltcs.

compare the patient-selected nose method and conventional method in laparoscopic total colon surgery

Eligibility criteria:
inclusion criteria: * laparoscopic total colectomy patients exclusion criteria: * no